Purpose: to study the effect of low-level laser therapy (LLLT) in correction of blood hemodynamic and rheological parameters after surgery for head and neck cancer.Material and Methods. The study included 134 head and neck cancer patients with a median age of 54.24 ± 12.7 years (range: 23–78 years). There were 39 (29.1 %) men and 95 (70.9 %) women. To assess the effectiveness of LLLT, all patients were divided into 3 groups. Group I included 45 patients, who received conventional therapy without the use of LLLT. Group II consisted of 45 patients, who received conventional therapy in combination with LLLT. Group III included 44 patients, who received LLLT alone. Azor 2K-02 was used as a source of LLLT in the red to near infrared spectral range. Characteristics of blood flow in the vessels of the neck and the rheological properties of blood, as well as the parameters of spontaneous platelet aggregation and the content of soluble fibrinmonomer complexes in the blood plasma of patients were studied.Results. The data obtained indicated that the use of LLLT promoted normalization of blood rheological properties in patients, who underwent surgery. Normalization of blood rheological properties occurred faster and lasted for a longer period. In patients, who received conventional therapy in combination with LLLT, the hemodynamic and rheological parameters of blood were improved 2–14 days after therapy, whereas in patients receiving conventional therapy alone, this improvement was seen 30 or more days after therapy.Conclusion. LLLT in combination with conventional therapy was shown to have a positive effect on hemodynamic and rheological parameters after surgery for head and neck cancer.

Takayasu arteritis (TA) is a systemic vasculitis with predominatly lesions of aorta and its large branches. In some cases pulmonary arteries (PA) are involved in the pathological inflammatory process and lead to the formation of pulmonary hypertension and significantly worse the prognosis. Timely development of lesion of PA, appointment of adequate therapy and surgical treatment can prevent irreversible damage of blood vessels and improve the prognosis. Perioperative administration of interleukin-6 inhibitor inhibitor (tocilizumab) in at patients with indications for vascular surgery, including angioplasty PA, should be considered as a promising approach to control the inflammatory activity of TA, reduce the dose of glucocorticoids and the risk of postoperative complications. We present the clinical experience of significant improvement in the patients condition was achieved by using two-stage balloon angioplasty on the background of control of the disease activity with interleukin-6 tocilizumab intravenously and specific therapy with riociguat and iloprost.

Colitis cystica profunda is a rare nonmalignant disease, characterized by an inflammation of mucous coat of intestine and formation of submucous cysts. The clinical picture of this pathology and oncological diseases of colon and rectum is similar. It is very difficult and important to differentiate this disease from colorectal cancer to protect the patient from unjustified mutilating surgery. Nowadays either in Russian and foreign scientific literature there are single reports dedicated to this disease. In our opinion the publication of this clinical case and analysis of scientific literature devoted to this subject is currently important. In this article there is a short review of modern state of problem of diagnostics and treatment of colitis cystica profunda. Also there is an own rare clinical observation of a patient who was diagnosed with colitis cystica profunda.

In this pilot trial we analyzed the correlation between neoangiogenesis and psychological status in ovarian cancer patients. We found the correlation between depression levels and serum vascular endothelial growth factor levels in ovarian cancer patients – coefficient of rank correlation (ρ) was 0.42 (95 % confidence interval 0.01–0.72; р < 0,05), that suggests the relationship between this parameters.

Tumors of the reproductive system account for the highest percentage of incidence in female oncological diseases in Russia 36.7%. Ovarian cancer is the leading cause of death among gynecological cancer diseases. Diagnosis and treatment of cancer may cause psychological trauma and provokepost-traumatic stress disorder (PTSD). According to various studies, PTSD incidence among cancer patients ranges from 3% (in the early stages) to 45% in patients after treatment, and up to 80% in those with recurrent disease.

Administration of an immunomodulator, galavit, for stage II-III non-small lung cancer along with standard therapy was followed by immunological vigor improvement by the end of the course. CD3, CD4, IgA, IgM and IgG indices were normal in more than 80% of the study group by day 51 after surgery; CD8, CD20 and HLA-DR--in more than 50%; CD16--in 45.2%. In control, by day 51, normal IgG and HLA-DR levels were reported in 60%. The remaining indices were normal in less than 50%. Our results point to immunological vigor improvement due to use of galavit. The drug is well tolerated, has neither side effects nor toxicity.

The article presents the results of a clinicoimmunological examination of 61 patients with stage II-III non-small cell cancer of the lung. It has been shown that in the presence of immunomodulating therapy all links of the immunity are being recovered.

The multifunctional mammalian protein YB-1 is involved in multiple DNA- and mRNA-dependent events in the cell and regulates gene expression at different levels. The intracellular localization and relative mRNA content of YB-1 in the breast tumors were studied. The presence of cells with nuclear YB-1 localization in the tumor cell population is a poor predictor that correlates with larger tumors (more than 5 cm). The high YB-1 mRNA content in the breast tumors promotes metastasis of small neoplasms and patients with breast cancer who have high tumor tissue YB-1 mRNA levels may referred to as an early distant metastasis risk group. The findings suggest that combined determination of YB-1 intercellular localization and mRNA levels can ensure a more reliable prognosis of breast cancer.

The article presents the results of a clinicoimmunological examination of 61 patients with stage II-III non-small cell cancer of the lung. It has been shown that in the presence of immunomodulating therapy all links of the immunity are being recovered.

This article presents a review of literature concerning the impact of stress on immunity of cancer patients and the results of a research on associations between distress parameters and cell immunity in patients with breast cancer (BC) accomplished by researchers of the Laboratory for Post-Traumatic Stress of the Institute of Psychology RAS and physicians of the chair of oncology and radiation therapy of the Moscow State Medico-Stomatological University. In previous research, the authors have already shown that BC happens to be a traumatic stressor that can cause post-traumatic stress disorder (PTSD): the condition that fits the clinical picture of PTSD has been found in 24% of patients. These patients demonstrate obsessive thoughts about the disease, avoidance behavior concerning the situations that remind of it and increased physiological response as a reaction to any thought or image associated with the trauma. The patients with high levels of post-traumatic stress seem to show lower values of T-lymphocytes (CD4+). Besides, the CD4+ level seems to correlate with a number of distress parameters such as obsessive-compulsive symptoms, interpersonal sensitivity, depression, anxiety and psychotic features (a number of correlations concerns also the immune regulation index CD4/CD8). The issue of direct impact of stress on the origin and development of cancer needs further investigations but so far there is evidence that intense post-traumatic reactions, which are observed in some BC-patients, can aggravate the course of the oncological disorder and influence negatively the patients' immune status, thus enhancing the risk of relapse.

Немелкоклеточный РЛ представляет собой морфологически неоднородную группу, включающую в основном плоскоклеточный рак (70–75%), аденокарциному (20–25%) различной дифференцировки и другие, редкие формы рака. Они объедены в одну группу немелкоклеточного рака по органному принципу и близким отдаленным результатам. Единственным радикальным методом лечения немелкоклеточного РЛ остается хирургический [3]. В настоящее время основным контингентом больных, подвергающихся хирургическому лечению, являются больные с II–III стадией опухолевого процесса. Так как злокачественный опухолевый процесс, оперативное вмешательство и развивающиеся в послеоперационном периоде осложнения приводят к значительной иммуносупрессии, целью данной работы явилось исследование иммунологической эффективности применения иммуномодулятора Галавит у больных немелкоклеточным РЛ II–III стадии.

The medicine Galavit is an anti-inflammatory and immunomodulating drag that mediates immune system via macrophages. The drag is used in oncological and surgical practice.

In clinical observation on 248 patients with breast cancer IIb-III-b stages given radiotherapy on breast gland, parasternal and axillary-subclavian regions (total doses 40 Gr for each) before mastectomy was shown, that use LF im 2-3 times a week through the course of therapy decreases statistically significant pancytopenia, induced by radiation. Quantity leukocytes was even increase in a process of therapy. Frequency of anemia and lyphopenia was decreased almost 3 times. E-RFC were depressed also more slight, then in the group without immunocorrection and after mastectomy practically, restored. IFN-gamma production by T-lymphocytes was not changed and essentially more high then in the comparative group. The presented data are shown, that LF provides a defensive action on hematological indices and immune effectors function in oncological patients during radiotherapy.